Prolaris® + AI Prostate Cancer Prognostic Test

The Prolaris® + AI Test: More insight for your prostate cancer care decisions

If you’ve been diagnosed with localized prostate cancer, you may be considering active surveillance or treatment. The Prolaris® + AI Test gives your doctor additional information from your biopsy, including artificial intelligence (AI)-assisted analysis, to help build a more complete understanding of your cancer and guide conversations about your care.

Understanding your prostate cancer takes more than one piece of information.

Every prostate cancer is different.

That's why healthcare providers look at multiple pieces of information when discussing your care, including your biopsy results, your overall health and how your tumor behaves.

The Prolaris + AI Test brings those insights together into one report, giving your doctor a more complete picture of your cancer and helping guide conversations about your treatment options.

Clinical information

What your healthcare provider already knows about your diagnosis:

  • Age at biopsy
  • PSA prior to biopsy
  • Clinical T stage
  • Positive cores
  • Gleason score

Tumor biology

What your genes reveal about how aggressive your cancer is behaving.1,2

AI-assisted tissue analysis

Additional insight from patterns found in your biopsy tissue to help determine likelihood of higher Gleason score at next biopsy for patients appropriate for active surveillance.3

One report

A fuller picture to help guide your care.

View Prolaris + AI patient guide

What is the Prolaris + AI Test for prostate cancer

The Prolaris Test has long helped healthcare providers better understand how a patient's prostate cancer is likely to behave by analyzing the activity of genes within the tumor. With the addition of the AI metric, the test can now better help you and your doctors answer questions like:

  • Is active surveillance an appropriate option for me?
  • If I choose active surveillance, how closely should I be monitored?
  • Should I consider treatment instead?
  • If treatment is recommended, how intensive should it be?

How the Prolaris + AI prostate cancer test works

Using digital images from your existing biopsy tissue, the new AI metric analyzes complex tissue patterns that may provide additional information about your cancer. Combined with your Prolaris genomic score and clinical information, it gives your doctor a more complete picture to help guide decisions about your care.

The AI enhancement works with the biopsy tissue you've already provided, so there's no need for an additional biopsy or procedure.

How can AI inform active surveillance monitoring?

When you’re considering active surveillance, every piece of information matters.

The Prolaris + AI enhancement helps estimate the likelihood of a higher Gleason score at a future biopsy for eligible patients considering active surveillance.3

Combined with the Prolaris genomic score and your clinical information, it gives your doctor additional insight that may help:

  • Determine whether active surveillance may be appropriate
  • Personalize how closely your cancer should be monitored
  • Guide conversations about treatment options

Treatment decisions should always be made together with your healthcare provider.

When considering prostate cancer treatment

If treatment is being considered, another important question is how much treatment may be appropriate for your individual cancer.

The Prolaris + AI Test provides personalized information that can help you and your doctor discuss whether a single form of treatment or multiple forms of treatment may be appropriate.

For patients considering radiation therapy, the Prolaris Test can also provide information to help determine whether adding hormone therapy, also called androgen deprivation therapy (ADT), may provide additional benefit, or whether it may be appropriate to avoid ADT and its potential side effects.

What makes the Prolaris + AI Test different?

The Prolaris + AI Test provides two independent measurements designed specifically to help guide active surveillance decisions.

  1. Confirms active surveillance4-6
  2. Tailors personalized active surveillance follow up3

Clinically validated for active surveillance

Clinically validated in untreated patients, making it uniquely suited to help guide safe active surveillance selection4-6

Guides the ADT conversation

Helps identify which men would benefit from adding hormone therapy (ADT) and who may be appropriate to avoid it.

Is the Prolaris + AI Test for prostate cancer right for me?

Every prostate cancer diagnosis is unique, and your care plan should be too. The Prolaris + AI Test is designed for patients who have been newly diagnosed with localized prostate cancer, or are currently on active surveillance. By combining genomic insights with AI-assisted tissue analysis, it provides additional information to help you and your doctor have more informed conversations about active surveillance and treatment.

You may want to ask your doctor about the Prolaris + AI Test if you’re wondering:

  • Is active surveillance an appropriate option for me, or should I consider treatment?
  • How likely is my cancer to grow or spread?
  • How closely should my cancer be monitored over time?
  • Would my treatment plan benefit from additional therapies, such as hormone therapy (ADT)?

Download the Prolaris + AI patient guide

Take the next step with the Prolaris + AI Test

Navigate crucial prostate cancer treatment decisions – with the right answers at the right time.

Act now, to start personalizing your prostate cancer treatment








Hidden Fields









We are here to help! If you can answer ‘yes’ to any of the following, we can provide educational information to your Urologist.


Are you:

  • Newly diagnosed with prostate cancer?

  • Currently on active surveillance?

If you are interested and would like us to reach out to your provider, please fill out their information below






By submitting this form, you agree to be contacted with newsletters, marketing or promotional materials, and other information that may be of interest to you. You may unsubscribe from these communications by following the unsubscribe link or the instructions provided in the communication we send. The information you submit is governed by our Privacy Notice and our website Terms of Use.

You’ll receive a personalized follow up call from a Myriad customer service representative, with the caller ID displaying Myriad Genetics Support Team – Prolaris Test.

Frequently asked questions about the Prolaris + AI Test and
prostate cancer

  • What is active surveillance for prostate cancer?

    Active surveillance is a treatment approach for some patients with localized prostate cancer. Rather than treating the cancer right away, your doctor closely monitors it over time through regular PSA testing, checkups and, when appropriate, additional imaging or biopsies.

    The goal is to monitor the cancer carefully and begin treatment if there are signs that it is becoming more aggressive.
  • Does active surveillance mean I'm not treating my prostate cancer?

    No. Active surveillance is an active, personalized care plan, not a "wait and see" approach. It involves regular monitoring to help your doctor track any changes in your cancer over time.

    The Prolaris + AI Test provides additional information that may help your doctor determine whether active surveillance may be appropriate and how closely your cancer should be monitored.
  • Does AI replace my provider’s judgment?

    No. The AI enhancement provides additional information for your doctor to consider alongside your medical history, biopsy findings and other clinical information. Treatment decisions should always be made together with your healthcare provider.
  • Will I need another prostate biopsy?

    No. The AI enhancement uses digital images from your existing biopsy tissue, so no additional biopsy or tissue sample is needed.
  • Does the Prolaris + AI Test decide whether I need prostate cancer treatment?

    The Prolaris + AI Test does not make treatment decisions, but it can help determine whether a patient may benefit from a single form of treatment, such as surgery, or multiple forms of treatment, such as surgery, radiation and ADT.

    Your care plan should always be based on your provider’s clinical judgment and your individual needs.
  • How is AI used in the Prolaris + AI Test for prostate cancer?

    The AI enhancement analyzes digital images of your existing biopsy tissue to identify complex tissue patterns that may provide additional insight into your cancer. Combined with your Prolaris genomic score and clinical information, it helps provide a more complete picture of your cancer.
  • How much does the Prolaris + AI Test cost?

    The amount you may pay for the Prolaris + AI Test depends on your insurance plan and individual financial situation. Myriad offers resources to help you understand your coverage and potential costs.

    Medicare coverage
    Medicare covers Prolaris Testing at 100%.

    Most patients have no out-of-pocket cost7

    Financial assistance is available
    Financial assistance may be available for eligible patients who need help with the cost of testing.

    Have questions about cost or coverage? The Myriad customer support team can help answer questions about insurance, testing benefits and getting started.

    Email: [email protected]

    Phone: (855) 469-7765

Talk with your provider about the Prolaris + AI Test for prostate cancer

If you've recently been diagnosed with localized prostate cancer, ask your urologist whether the Prolaris + AI Test may help inform your care plan

Download the Prolaris + AI patient guide

References

  1. Cuzick J, Stone S, Fisher G, et al. Validation of an RNA cell cycle progression score for predicting death from prostate cancer in a conservatively managed needle biopsy cohort. Br J Cancer. 2015;113(3):382-389.
  2. Morgan TM, et al. Clin Genitourin Cancer. 2026 May 20:102586. doi: 10.1016/j.clgc.2026.102586
  3. Mabey B, et al. Development and validation of a digital pathology artificial intelligence (DPAI)-derived risk score predicting Gleason grade group reclassification for patients who are candidates for active surveillance. Future Oncol. 2026 Jun 16:1-9. doi: 10.1080/14796694.2026.2686438
  4. Lin DW, Crawford ED, Keane T, et al. Identification of men with low-risk biopsy-confirmed prostate cancer as candidates for active surveillance. Urol Oncol. 2018;36(6):310.e7-310.e13.
  5. Kaul S, Wojno KJ, Stone S, et al.Clinical outcomes in men with prostate cancer who selected active surveillance using a clinical cell cycle risk score. Per Med. 2019;16(6):491-499.
  6. Lenz L, Clegg W, Iliev D, et al. Active surveillance selection and 3-year durability in intermediate-risk prostate cancer following genomic testing. Prostate Cancer Prostatic Dis. 2025;28(2):427-434.
  7. Based on a review of past claims data, the majority of patients face no out-of-pocket costs for their Prolaris Test. Last update 2024.

This page includes AI generated images. Any similarity or resemblance to persons, living or dead, is purely coincidental.

©2026 Myriad Genetics, Inc. Myriad Genetics, Prolaris and their respective logos, are registered trademarks of Myriad Genetics, Inc. and its subsidiaries in the United States and other jurisdictions.